Abstract
mRNA-based vaccines show a revolutionary prophylactic and therapeutic potential. However, both the mRNA itself and the nanocarrier used for its delivery place unique demands on the analytical methods used to ensure vaccine quality. We will show that MD-FFF is a very powerful, high-data-content methodology that nicely complements and extends beyond batch-phase techniques for physical, chemical and stability analysis of these next-generation vaccines in the industry setting.
